FeesSafety
Pluang+

Lawsuit probes Gildan Activewear for alleged misleading info after stock drops 18.7%.

Market News
21 Sep 2026
PRNewsWire
View Source
Bearish
Lawsuit probes Gildan Activewear for alleged misleading info after stock drops 18.7%.

Rosen Law Firm is investigating potential securities claims against Gildan Activewear following allegations that the company issued misleading business information. This comes after a short seller report by Jehoshaphat Research questioned Gildan's organic growth and sales practices, leading to an 18.7% drop in its stock on June 16, 2026. Investors who bought Gildan securities may join a class action lawsuit to seek compensation without upfront fees. Rosen Law Firm, known for its expertise in securities class actions, is preparing to represent affected shareholders.

Gildan Activewear is the subject of a securities class action investigation following allegations of misleading business information. For readers following the Consumer Cyclical sector, here is Pluang's market snapshot as of Sep 22, 2026 01:02 WIB: out of 110 priced US stocks, 85 rose and 24 fell. Notable movers include PLBY at USD 1.09 (+3.81%), ULTA at USD 560.44 (+3.60%) with 100% buy order activity, and W at USD 106.13 (+3.58%).

More News

Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...

Company Fundamentals
Bullish
2 hours ago
Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...

Company Fundamentals
Bullish
2 hours ago
New Proof of Human feature links Alien ID to Solana wallets for real user verification.

New Proof of Human feature links Alien ID to Solana wallets for real user verification.

A new Proof of Human feature allows users to link an Alien ID to any Solana wallet, verifying that a real person controls the wallet. This initiative aims to enhance trust and security in blockchain transactions by confirming human identity behind wa...

Protocol Fundamentals
Neutral
4 hours ago
Perioperative apalutamide plus ADT cuts risk of prostate cancer recurrence or death by 62% versus surgery alone

Perioperative apalutamide plus ADT cuts risk of prostate cancer recurrence or death by 62% versus surgery alone

New Phase 3 PROTEUS substudy results show that adding apalutamide plus androgen deprivation therapy (ADT) before and after surgery reduces the risk of prostate cancer recurrence or death by 62% compared to surgery alone in high-risk localized or loca...

Market News
Bullish
4 hours ago
AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker has introduced a comprehensive Business Class Flight Routes Guide to help travelers from the US explore premium flight options to 15 major international destinations across Asia, Europe, Africa, and Australia. The guide covers airlines, ...

Others
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App